专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060105329A1 Gene panel participating in liver regeneration 审中-公开
标题翻译：基因组参与肝再生
公开(公告)号：US20060105329A1
公开(公告)日：2006-05-18
申请号：US10469938
申请日：2002-03-13
申请人： Fumihiko Yokoya , Tomohisa Okutsu , Maiko Mori , Yoshiyuki Takahara , Hisao Fukuda , Hiroyuki Aburatani , Ichiro Sonaka
发明人： Fumihiko Yokoya , Tomohisa Okutsu , Maiko Mori , Yoshiyuki Takahara , Hisao Fukuda , Hiroyuki Aburatani , Ichiro Sonaka
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/6837 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/5082 , G01N33/5088 , G01N33/5091
摘要： A gene panel comprising a group of genes of which expression levels change in hepatocytes during liver regeneration as compared with those in a normal state is produced by the following steps: (a) the step of measuring expression levels of various genes in hepatocytes of a model animal in a normal state and expression levels of the genes during liver regeneration; (b) the step of comparing the expression levels, respectively; and (c) the step of identifying a group of genes of which expression levels change during liver regeneration.
摘要翻译：通过以下步骤产生包含一组在肝再生期间肝细胞中表达水平变化的基因组的基因组：（a）测量模型的肝细胞中各种基因的表达水平的步骤正常状态的动物和肝脏再生过程中基因的表达水平; （b）分别比较表达水平的步骤; 和（c）鉴定在肝再生过程中表达水平发生变化的一组基因的步骤。

2. 发明申请

US20050070606A1 Pharmaceutical agent for mitochondrial disorders 审中-公开
标题翻译：线粒体疾病药物
公开(公告)号：US20050070606A1
公开(公告)日：2005-03-31
申请号：US10917473
申请日：2004-08-13
申请人： Maiko Mori , Yoshiyuki Takahara , Sonoko Ishizaki , Ichiro Sonaka
发明人： Maiko Mori , Yoshiyuki Takahara , Sonoko Ishizaki , Ichiro Sonaka
IPC分类号： A61K31/198 , A61P3/10 , A61P25/00 , A61P25/10 , A61P25/14 , A61P25/16 , A61P25/28 , A61P27/02 , A61P43/00
CPC分类号： A61K31/198
摘要： The present invention provides a pharmaceutical agent (e.g., a therapeutic agent) for treatment of mitochondrial disorders, which is highly safe with minimal adverse effects. Thus, the pharmaceutical agent is extremely useful as a medical product for mitochondrial disorders. The present invention also provides a method for preventing, ameliorating and/or therapeutically treating mitochondrial disorders by administering the pharmaceutical agent of the present invention.
摘要翻译：本发明提供用于治疗线粒体疾病的药剂（例如，治疗剂），其具有高度安全性并且具有最小的不良反应。因此，药剂作为线粒体疾病的医疗产品是非常有用的。本发明还提供了通过施用本发明的药剂来预防，改善和/或治疗性地治疗线粒体疾病的方法。

3. 发明申请

US20050197398A1 Therapeutic agent for hepatic disease 审中-公开
标题翻译：肝病治疗剂
公开(公告)号：US20050197398A1
公开(公告)日：2005-09-08
申请号：US11066312
申请日：2005-02-28
申请人： Ichiro Sonaka , Shoji Fujitani
发明人： Ichiro Sonaka , Shoji Fujitani
IPC分类号： A61K31/198 , A61P1/16
CPC分类号： A61K31/198 , A61K2300/00
摘要： Pharmaceutical compositions which contain isoleucine, leucine, valine, and alanine as active ingredients, are useful for treating liver diseases such as hepatitis, liver cirrhosis, liver cancer, and the like via maintenance and improvement of albumin level in blood. In preferred embodiments, the mass ratio of isoleucine:leucine:valine is 1:1.9 to 2.2:1.1 to 1.3; the mass ratio of the total mass of isoleucine, leucine and valine: alanine is 1:0.05 to 10; and a daily dose per person contains isoleucine in an amount of 0.2-30.0 g, leucine in an amount of 0.2-30.0 g, valine in an amount of 0.2-30.0 g, and alanine in an amount of 0.2-50.0 g.
摘要翻译：含有异亮氨酸，亮氨酸，缬氨酸和丙氨酸作为活性成分的药物组合物可用于通过维持和改善血液中的白蛋白水平来治疗肝脏疾病如肝炎，肝硬化，肝癌等。在优选的实施方案中，异亮氨酸：亮氨酸：缬氨酸的质量比为1：1.9至2.2：1.1至1.3; 异亮氨酸，亮氨酸和缬氨酸：丙氨酸总质量的质量比为1:0.05至10; 并且每人每日剂量含有0.2-30.0g的异亮氨酸，0.2-30.0g的亮氨酸，0.2-30.0g的缬氨酸和0.2-50.0g的丙氨酸。

4. 发明授权

US07208523B2 Alanine- and glycine-containing therapeutic agent for hepatitis 失效
标题翻译：含丙氨酸和甘氨酸的肝炎治疗剂
公开(公告)号：US07208523B2
公开(公告)日：2007-04-24
申请号：US10196816
申请日：2002-07-18
申请人： Masayoshi Yamauchi , Ichiro Sonaka
发明人： Masayoshi Yamauchi , Ichiro Sonaka
IPC分类号： A01N37/12 , A01N37/44 , A61K31/195 , A61K39/29
CPC分类号： A61K31/195 , A61K31/198 , Y10S514/894 , A61K2300/00
摘要： The therapeutic agent for hepatitis, containing alanine and glycine, has only a slight toxicity and it can be administered either orally or intravenously to improve the liver function.
摘要翻译：含有丙氨酸和甘氨酸的肝炎治疗剂仅具有轻微的毒性，可口服或静脉内给药以改善肝功能。

5. 发明授权

US07094797B2 Organ fibrosis inhibitor 有权
标题翻译：器官纤维化抑制剂
公开(公告)号：US07094797B2
公开(公告)日：2006-08-22
申请号：US10875274
申请日：2004-06-25
申请人： Takashi Horie , Megumi Nakajoh , Ichiro Sonaka , Sonoko Ishizaki
发明人： Takashi Horie , Megumi Nakajoh , Ichiro Sonaka , Sonoko Ishizaki
IPC分类号： A61K31/415 , A61K31/195
CPC分类号： A61K31/198 , A61K31/4172 , A61K2300/00
摘要： An organ fibrosis inhibitor, in particular, a liver fibrosis inhibitor is provided, which contains histidine, preferable together with cysteine and/or cystine as active ingredients. Owing to the combined use, a remarkable effect of inhibiting organ fibrosis, in particular, liver fibrosis can be shown. These substances are usable as the desired active ingredients in the form of a drug or in the form of a food and drink. There is also provided an organ fibrosis inhibitor comprising the active ingredients as described above either separately or as a combination of one of them with a mixture of the other two ingredients. Thus, it is possible to present organ fibrosis inhibitors such as a liver fibrosis inhibitor which are applicable in the form used in health foods for improving and maintaining liver function and foods and drinks for sick people, as well as drugs for various organ diseases caused by fibrosis such as liver diseases.
摘要翻译：提供器官纤维化抑制剂，特别是肝纤维化抑制剂，其含有组氨酸，优选与半胱氨酸和/或胱氨酸一起作为活性成分。由于组合使用，可以显示抑制器官纤维化，特别是肝纤维化的显着效果。这些物质可用作药物形式的所需活性成分或食品和饮料形式。还提供了包含如上所述的活性成分的器官纤维化抑制剂单独地或作为其中之一与其它两种成分的混合物的组合。因此，可以提供适用于健康食品中用于改善和维持肝功能的形式的肝纤维化抑制剂，以及用于病人的食物和饮料的器官纤维化抑制剂以及由各种器官疾病引起的各种器官疾病的药物肝纤维化如肝病。

6. 发明申请

US20050020656A1 Organ fibrosis inhibitor 有权
标题翻译：器官纤维化抑制剂
公开(公告)号：US20050020656A1
公开(公告)日：2005-01-27
申请号：US10875274
申请日：2004-06-25
申请人： Takashi Horie , Megumi Nakajoh , Ichiro Sonaka , Sonoko Ishizaki
发明人： Takashi Horie , Megumi Nakajoh , Ichiro Sonaka , Sonoko Ishizaki
IPC分类号： A23L1/305 , A61K31/198 , A61K31/4172 , A61K45/06 , A61P1/16 , A61P1/18 , A61P9/00 , A61P11/00 , A61P13/00 , A61P17/00 , A61P19/00 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/64
CPC分类号： A61K31/198 , A61K31/4172 , A61K2300/00
摘要： An organ fibrosis inhibitor, in particular, a liver fibrosis inhibitor is provided, which contains histidine, preferable together with cysteine and/or cystine as active ingredients. Owing to the combined use, a remarkable effect of inhibiting organ fibrosis, in particular, liver fibrosis can be shown. These substances are usable as the desired active ingredients in the form of a drug or in the form of a food and drink. There is also provided an organ fibrosis inhibitor comprising the active ingredients as described above either separately or as a combination of one of them with a mixture of the other two ingredients. Thus, it is possible to present organ fibrosis inhibitors such as a liver fibrosis inhibitor which are applicable in the form used in health foods for improving and maintaining liver function and foods and drinks for sick people, as well as drugs for various organ diseases caused by fibrosis such as liver diseases.
摘要翻译：提供器官纤维化抑制剂，特别是肝纤维化抑制剂，其含有组氨酸，优选与半胱氨酸和/或胱氨酸一起作为活性成分。由于组合使用，可以显示抑制器官纤维化，特别是肝纤维化的显着效果。这些物质可用作药物形式的所需活性成分或食品和饮料形式。还提供了包含如上所述的活性成分的器官纤维化抑制剂单独地或作为其中之一与其它两种成分的混合物的组合。因此，可以提供适用于健康食品中用于改善和维持肝功能的形式的肝纤维化抑制剂，以及用于病人的食物和饮料的器官纤维化抑制剂以及由各种器官疾病引起的各种器官疾病的药物肝纤维化如肝病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式